44.210.77.106
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Pediatrics

FDA grants priority review for aflibercept in ROP

The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept (Eylea; Regeneron) injection to treat retinopathy of prematurity (ROP) in preterm infants. The target action date for the FDA decision is February 11, 2023. Data from 2 global Phase 3 trials...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-